New peer-reviewed, scientific study shows Vyleesi enhances sexual brain processing in premenopausal women with HSDD. Click here to learn more ›

Palatin Technologies Receives $1.1 Million From Sale of New Jersey State Tax Credits

CRANBURY, N.J., Jan. 17, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced today it has received net proceeds of approximately $1.1 million of non-dilutive funding through the New Jersey Economic Development Authority’s tax credit transfer program.  Palatin Technologies sold both New Jersey net operating losses and research and development tax credits to unrelated corporations.

Last year, Palatin Technologies received approximately $637,000 under this program.

About Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin’s website at http://www.palatin.com

SOURCE Palatin Technologies, Inc.

Scroll to Top